Lenvatinib

Form: Oral capsules

Strength: 4 mg , 10 mg

Reference Brands: Lenvima® (EU & US)

Category: Oncology Cancer Care

Lenvatinib, marketed as Lenvima® by Eisai, is a potent oral tyrosine kinase inhibitor (TKI) used in oncology to treat thyroid cancer, renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and endometrial carcinoma. Available in 4 mg and 10 mg capsules, Lenvatinib is approved in both the US and EU. It works by inhibiting tumor angiogenesis and cell proliferation. As a high-demand anticancer therapy, it is widely distributed by pharma B2B suppliers across the European and U.S. markets, ensuring GMP-compliant sourcing, consistent availability, and competitive pricing for hospitals, pharmacies, and oncology centers managing advanced cancers.